The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 16 of the 20 sources its claims cite were checked for support.
Abstract
Abstract Medulloblastoma is a prevalent, highly heterogeneous malignant pediatric brain cancer. In this study, we developed the Medulloblastoma Meta-Analysis portal, a web-based data analysis and visualization platform that consolidates clinical, molecular, and survival data of 898 patients from three major clinical trials (ACNS0331, ACNS0332, and SJMB03). The portal integrated clinical data with genomic mutations and DNA methylomes, enabling in-depth analyses of tumor subgroups and survival outcomes. Dynamic exploration and custom stratification of these data were made possible by the portal’s user-friendly visualization tools powered by the ProteinPaint framework, allowing users to select from a wide range of variables or customize their own. The Cox regression analysis tool in the portal demonstrated utility in examining the prognostic impact of variables across a heterogeneous dataset. Additionally, an in-depth exploration of medulloblastomas that harbor KBTBD4 mutations and their corresponding methylomes generated leads that could help improve molecular classification. These use cases underscore the portal’s utility in enhancing risk stratification, informing tailored therapeutic strategies, and revealing the complexities of molecular heterogeneity in patients with medulloblastoma. The portal, along with links to the tutorials and live figures, is freely available at https://viz.stjude.cloud/st-jude-childrens-research-hospital/visualization/medulloblastoma-integrative-analysis-portal~2882. Significance: The MB-meta portal facilitates risk stratification of patients using molecular, genomic, clinical, and demographic data, representing a significant step in neuro-oncology data sharing by offering an intuitive web-based platform for complex analyses.
Overview
CoChat Summary
TL;DR
The MB-meta portal integrates clinical, molecular, and survival data from 898 medulloblastoma patients across three clinical trials into a web-based analysis platform. Using it, the authors confirm MYC amplification, G3 group, and metastatic disease as poor PFS indicators in G3/G4 tumors and refine KBTBD4 mutation patterns across methylation subgroups.
Key findings
- The portal hosts 898 patients ages 3–22 from ACNS0331, ACNS0332, and SJMB03, with molecular groups WNT (n = 131), SHH (n = 151), G3 (n = 220), and G4 (n = 396); methylation data are available for all samples, sequencing for 754, and paired somatic/germline sequencing for 145.
- In a G3/G4 PFS Cox analysis restricted to standard- or high-dose craniospinal irradiation and excluding low-dose or carboplatin-containing regimens, poorer outcomes were observed for MYC amplifications (univariate HR = 5.94; 95% CI, 3.46–10.2; multivariate HR = 5.39; 95% CI, 3.1–9.38), G3 group (univariate HR = 2.48; 95% CI, 1.75–3.513; multivariate HR = 2.186; 95% CI, 1.464–3.263), and metastatic disease M+ (univariate HR = 2.9; 95% CI, 2.05–4.1; multivariate HR = 2.58; 95% CI, 1.8–3.69); iso17, age group, and gender did not significantly affect PFS.
- Manual review of nearly 700 tumors rescued KBTBD4 mutation calls in three samples and corrected mutation alleles for 21 tumors; 26 of 29 KBTBD4-mutated cases fell into two clusters, with 13 of 16 (81%) in the G3/G4-2 cluster harboring R313insPRR and 5 of 10 (50%) in the G3/G4-7 cluster harboring R312_R313insP.
- MYC amplifications were not exclusive to G3: most occurred in G3/G4-2 and G3/G4-3, but a few were classified as G3/G4-5 and G3/G4-6 (G4), and one MYC-amplified G3 case was unclassified.
Methods
- Retrospective cohort from three medulloblastoma clinical trials, including patients 3–22 years old; tumors were molecularly classified into WNT, SHH, G3, and G4 using DNA methylation profiles overlaid with next-generation sequencing mutations, with endpoints OS, EFS, and PFS.
- The MB-meta portal provides a data dictionary and interactive visualizations; analyses used t-SNE clustering, Fisher exact tests, Kaplan–Meier/log-rank survival comparisons, and Cox proportional hazards models, with structural modeling via AlphaFold Colab and UCSF Chimera.
- For the G3/G4 PFS example, the cohort was filtered to patients receiving standard- or high-dose craniospinal irradiation, excluding low-dose craniospinal irradiation and carboplatin-containing regimens; a custom iso17 variable was created from 17p loss and 17q gain.
Limitations
- Stated: KBTBD4 findings should be experimentally validated; binding affinities of newly identified KBTBD4 cases remain to be experimentally validated; the effect of a frameshift mutation on transcription cannot be ascertained because of a lack of RNA sequencing data; and further investigation is required to determine whether the homozygous KBTBD4 mutation relates to M+ metastatic status.
- Stated/evident: Some cases were unclassified or had low confidence scores (PARPDA CS = 0.47; SJMB067030 CS = 0.69; a G3/G4-3 case CS = 0.6; an overlapping unclassified case CS < 0.5), and one rescued case clustered closely with G3/G4-3 despite being classified as G3/G4-2.
- Evident from text: the analyses are secondary analyses of existing trial cohorts, and no independent validation cohort is described in the provided text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
8 Valid · 4 Not valid · 1 Not checked · 45 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“we developed the Medulloblastoma Meta-Analysis (MB-meta) portal, which integrates clinical, genomic, and survival data from 898 patients across three major medulloblastoma clinical trials (16–18).”
- Also stated in: § MB-meta portal overview · plain
“The MB-meta portal hosts extensive data from three clinical trials (ACNS0331, ACNS0332, and SJMB03), enabling integrative analysis of the clinical and molecular features of the tumors (16–18).”
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Introduction
What the sources say
- Supportedcites [16] Leary, 2021, Efficacy of carboplatin and isotretinoin in children with high-risk medulloblastoma: a randomized clinical trial from the children’s oncology group, JAMA Oncol source
The figure captions identify this paper as the Children's Oncology Group ACNS0332 study and show that it reports clinical characteristics, molecular data, and survival outcomes. In the citing sentence, this source serves to identify one of the three trials, not to substantiate the portal's combined total of 898 patients. (LLM, conf=0.88)
- Supportedcites [17] Michalski, 2021, Children’s oncology group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma, J Clin Oncol source
The Methods identify this paper as the ACNS0331 trial, and the Results report its patient outcomes and molecular profiling. In the citing sentence, this source serves to identify one of the three trials used by the authors’ portal; the portal and its 898-patient total are the citing authors’ own description, not findings attributed to this individual trial paper. (LLM, conf=0.90)
- Supportedcites [18] Gajjar, 2021, Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03), J Clin Oncol source
The Introduction identifies SJMB03 as a multi-institutional phase III trial, and the Study Patients section reports its medulloblastoma cohort and molecular analyses. The citation identifies SJMB03 as one of the trials used by the citing authors; it need not independently describe their MB-meta portal or its combined patient count. (LLM, conf=0.91)
plainn = 898- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § MB-meta portal overview · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The most prevalent mutation, an insertion at R313insPRR (7, 23–26), has been functionally characterized as enabling interaction with neosubstrates, such as small corepressor coREST.”
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Results > Integrating KBTBD4 driver mutation status on methylome t-SNE leads to novel insights in subgroup classification
What the sources say
- Partly supportedcites [7] Chen, 2022, Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation, Cell Death Differ sourceExperimental — accuracy not yet measured
The Results section, “Medulloblastoma-associated KBTBD4 mutations drive recognition of the CoREST complex” (page not provided), reports that R313PRR interacts with CoREST whereas wild-type KBTBD4 does not. It calls R313PRR the most recurrent mutation in group 3 medulloblastomas, but does not establish that it is the most prevalent KBTBD4 mutation overall. (LLM, conf=0.83)
- Could not verifycites [23] Williamson, 2022, Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development, Cell Rep sourceExperimental — accuracy not yet measured
The Results passage on RNA editing and the Methods passage listing analyzed mutations do not mention KBTBD4. Searches of our copy for R313insPRR, CoREST, and neosubstrate interaction found no passage addressing the mutation’s prevalence or functional characterization. (LLM, conf=0.76)
- Partly supportedcites [24] Lee, 2019, Recurrent KBTBD4 small in-frame insertions and absence of DROSHA deletion or DICER1 mutation differentiate pineal parenchymal tumor of intermediate differentiation (PPTID) from pineoblastoma, Acta Neuropathol sourceExperimental — accuracy not yet measured
The paper’s main text (page not provided) reports the p.R313delinsPRR insertion in all three PPTID tumors studied. It does not report an interaction with coREST or other neosubstrates; instead, it says the functional mechanism was uncertain and required future study. The finding in three tumors also does not establish that this is the most prevalent KBTBD4 mutation overall. (LLM, conf=0.89)
- Not checked — no full text of the sourcecites [25] Vasiljevic, 2023, Histopathology and molecular pathology of pediatric pineal parenchymal tumors, Childs Nerv Syst source
- Not checked — no full text of the sourcecites [26] Jones, 2024, A pineal parenchymal tumor of intermediate differentiation in an octogenarian contains a rare KBTBD4 insertion, Int J Surg Pathol source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Considering the driver status of KBTBD4 mutations and the tendency of variant-calling pipelines to miss or incorrectly call such complex mutations, we manually reviewed the tumor DNA sequencing data for nearly 700 tumors in the portal (27).”
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Results > Integrating KBTBD4 driver mutation status on methylome t-SNE leads to novel insights in subgroup classification
What the sources say
- Partly supportedcites [27] Paul, 2023, ppBAM: proteinpaint BAM track for read alignment visualization and variant genotyping, Bioinformatics sourceExperimental — accuracy not yet measured
The Introduction and Methods §2.3 describe ppBAM as a tool for manually reviewing variants in cancer sequencing data accessible through the NCI Genomic Data Commons. They do not report that the source-paper authors reviewed nearly 700 tumors; that review is described as the citing authors’ own work. (LLM, conf=0.82)
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The visualizations on the portal are interoperable, allowing for dynamic toggling between plots.”
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Results > Interactive visualization features on the portal
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Altogether, cases harboring iso17—regardless of MYC status—had no difference in outcomes compared with the rest of the G3/G4 cohort”
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Results > Cox regression analysis facilitates evaluation of prognostic features that determine PFS in G3/G4 medulloblastomas
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
24 more claims
Create a free account to see all 58 claims and every source verdict.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 10
- The quote only partly states this claim. 1
- Borderline: one of the tests for a substantial claim is unclear. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Results > Cox regression analysis facilitates evaluation of prognostic features that determine PFS in G3/G4 medulloblastomas
“a few cases were classified as subgroup G4/G4-4 (G3), subgroup G3/G4-5 (G4), and subgroup G4/G4-6 (G4; Supplementary Fig. S1B).”
§ The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients > Results > Cox regression analysis facilitates evaluation of prognostic features that determine PFS in G3/G4 medulloblastomas
“the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4”
Citations
Cites
The FAIR Guiding Principles for scientific data management and stewardship
Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L. B., Bourne, P. E., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.18 · Cited by 18,423 · cited 2×
“In lieu of the importance of data-sharing initiatives as outlined by the NIH (28), the ProteinPaint platform is designed for open-ended data exploration and real-time analysis, with massive scalability, flexibility for multimodal data integration, and an intuitive web-based user interface for data…”
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
ColabFold - Making protein folding accessible to all
Mirdita, M., Schütze, K., Moriwaki, Y., Heo, L., Ovchinnikov, S., & Steinegger, M. (2021) · doi:10.1101/2021.08.15.456425 · Cited by 9,391 · cited 1×
“Models for KBTBD4 Kelch domain repeat for the variants were generated using AlphaFold Colab (19).”
Molecular subgroups of medulloblastoma: the current consensus
Taylor, M. D., Northcott, P. A., Korshunov, A., Remke, M., Cho, Y.-J., Clifford, S. C., Eberhart, C. G., Parsons, D. W., Rutkowski, S., Gajjar, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0922-z · Cited by 1,936
Self-citationIntertumoral Heterogeneity within Medulloblastoma Subgroups
Cavalli, F. M. G., Remke, M., Rampasek, L., Peacock, J., Shih, D. J. H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.005 · Cited by 1,219
The whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112 · cited 5×
“In particular, DNA methylation profiling coupled with machine learning algorithms has identified eight molecular subgroups within G3 and G4 (5, 8, 14, 15).”
InfluentialSelf-citationDissecting the genomic complexity underlying medulloblastoma
Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., et al. (2012) · Nature · doi:10.1038/nature11284 · Cited by 839 · cited 1×
“…found in G3 and G4 tumors include amplifications of MYC and OTX2 , activation of GFI1B or GFI1 , mutations in KBTBD4 , enhancer hijacking of PRDM6 , mutations in KDM6A , large cell/anaplastic histology, loss of chromosome 10, presence of isochromosome 17q (iso17), and amplification of CDK6 (7–11).”
Self-citationMedulloblastoma exome sequencing uncovers subtype-specific somatic mutations
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012) · Nature · doi:10.1038/nature11329 · Cited by 750
Self-citationRisk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S. C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1569-6 · Cited by 654 · cited 2×
“This analysis confirms MYC amplifications, G3 molecular group, and the presence of metastatic disease—but not iso17—as key prognostic indicators of poor outcome in G3 and G4 cases across a population of patients with medulloblastoma treated with standard regimens (20, 21).”
Self-citationMEDULLOBLASTOMA CEREBELLI: A COMMON TYPE OF MIDCEREBELLAR GLIOMA OF CHILDHOOD
BAILEY, P. (1925) · Archives of Neurology & Psychiatry · doi:10.1001/archneurpsyc.1925.02200140055002 · Cited by 398 · cited 1×
“Medulloblastoma, initially characterized in the early 1920s, is among the most prevalent malignant pediatric brain neoplasms (1–3).”
Cited by
Lu, C., Matt, G. Y., Paul, R., Wang, J., Sioson, E., Gangwani, K., Acić, A., Willems, A. R., Peraza, A. Z., Reilly, C. A., et al. (2026) · Blood · doi:10.1182/blood.2025032031 · Cited by 1
Self-citation
Metadata
- Authors
- Gangwani, K., Lu, C., Dhanda, S. K., Sioson, E., Zaldívar Peraza, A., Matt, G. Y., Paul, R., Wang, J., Reilly, C., Acić, A., Smith, K. S., Lin, T., Li, Q., Northcott, P. A., Robinson, G. W., & Zhou, X.
- Affiliations
- St. Jude Children's Research Hospital (US)
- 1Department of Computational Biology, St. Jude Children’s Research Hospital, Memphis, Tennessee.
- Corresponding author
- Robinson, Giles W.
- Zhou, Xin
- ORCID
- Venue
- Cancer Research
- Published
- 2025-11-05
- Volume
- 85
- Issue
- 24
- Pages
- 4890-4898
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC12703356
- OpenAlex
- W4415926276
- Semantic Scholar
- 649ec91f29f7baa2771531eb56dffdb7c07c8167
- Cited by
- 1
- References
- 30
- Citations by year
- 2026: 1
- FWCI
- 0.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Research (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- Funders
- National Cancer Institute (P30CA021765)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Keywords
- medulloblastoma, pediatric brain tumors, web-based data portal, DNA methylation, tumor subtypes, survival outcomes, risk stratification, molecular classification, Cox proportional hazards model, clinical trials
- MeSH terms
- Cerebellar Neoplasms, Child, Humans, Medulloblastoma, Mutation, Prognosis, DNA Methylation, Genomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients. https://app.cochat.ai/papers/10.1158/0008-5472.can-24-4976
- The paper
- Gangwani, K., Lu, C., Dhanda, S. K., Sioson, E., Zaldívar Peraza, A., Matt, G. Y., Paul, R., Wang, J., Reilly, C., Acić, A., Smith, K. S., Lin, T., Li, Q., Northcott, P. A., Robinson, G. W., & Zhou, X. (2025). The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients. Cancer Research. https://doi.org/10.1158/0008-5472.can-24-4976
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.